

This is a published notice on the Find a Tender service: <https://www.find-tender.service.gov.uk/Notice/001628-2026>

Planning

Market Engagement for Onasemnogene Abeparvovec (Zolgensma®) Service & Onasemnogene Abeparvovec Intrathecal (OAV101 IT) Service

NHS England

F01: Prior information notice

Reducing time limits for receipt of tenders

Notice identifier: 2026/S 000-001628

Procurement identifier (OCID): ocds-h6vhtk-060244

Published 8 January 2026, 5:02pm

Section I: Contracting authority

I.1) Name and addresses

NHS England

Wellington House, 133-135 Waterloo Rd

London

SE1 8UG

Contact

Surinder Kahlon

Email

surinder.kahlon@nhs.net

Country

United Kingdom

Region code

UKJ1 - Berkshire, Buckinghamshire and Oxfordshire

Internet address(es)

Main address

<https://www.england.nhs.uk/>

Buyer's address

<https://www.england.nhs.uk/>

I.3) Communication

The procurement documents are available for unrestricted and full direct access, free of charge, at

<https://atamis-1928.my.site.com/s/Welcome>

Additional information can be obtained from the above-mentioned address

Tenders or requests to participate must be submitted electronically via

<https://atamis-1928.my.site.com/s/Welcome>

Tenders or requests to participate must be submitted to the above-mentioned address

Electronic communication requires the use of tools and devices that are not generally available. Unrestricted and full direct access to these tools and devices is possible, free of charge, at

<https://atamis-1928.my.site.com/s/Welcome>

I.4) Type of the contracting authority

Body governed by public law

I.5) Main activity

Health

Section II: Object

II.1) Scope of the procurement

II.1.1) Title

Market Engagement for Onasemnogene Abeparvovec (Zolgensma®) Service & Onasemnogene Abeparvovec Intrathecal (OAV101 IT) Service

Reference number

C410884

II.1.2) Main CPV code

- 85100000 - Health services

II.1.3) Type of contract

Services

II.1.4) Short description

The key objective of the Market Engagement Exercise is to seek feedback from the market regarding levels of interest, capability and capacity in relation to delivering the onasemnogene abeparvovec (zolgensma®) service and the onasemnogene abeparvovec intrathecal (OAV101 IT) service

II.1.5) Estimated total value

Value excluding VAT: £0.01

II.1.6) Information about lots

This contract is divided into lots: No

II.2) Description

II.2.3) Place of performance

NUTS codes

- UK - United Kingdom

II.2.4) Description of the procurement

The key objective of the Market Engagement Exercise is to seek feedback from the market regarding levels of interest, capability and capacity in relation to delivering the onasemnogene abeparvovec (zolgensma®) service and the onasemnogene abeparvovec intrathecal (OAV101 IT) service.

The commissioner is interested in receiving feedback from the market on their capability and capacity to deliver services for zolgensma® or combined (zolgensma® and OAV101 IT).

It is also anticipated that the findings from this market engagement exercise will assist in the decision-making for the approach to commissioning the Service(s).

If, as a result of the market engagement, competition is absent or minimal, in any of the potential Lots/Regions, the Commissioner may use the Most Suitable Provider Process or Direct Award Process C. Where competition is absent, Direct Award Process A may be utilised. If, as a result of the market engagement, competition is apparent in a potential Lot/Region, a Competitive Process may be undertaken to award the contract for that Lot.

Service Summary:

Spinal muscular atrophy, or SMA, is a rare genetic disorder that causes muscle weakness and progressive loss of movement. The severity of SMA can vary greatly between individuals. Historically, the condition has been classified into different types, determined by clinicians at the time of diagnosis. This classification is based on both the age at which symptoms first appear, and the highest level of motor function achieved by the patient.

The types range from type 0, the most severe form, where symptoms are present before birth and most affected infants don't survive past 6 months, through to type 4, which develops in adulthood and is associated with mild motor impairment and a normal life span. However, because the disease presents so variably, consistently categorising patients into these types at the point of diagnosis can be challenging.

Onasemnogene abeparvovec (zolgensma®) is a single-use gene replacement therapy made of a viral vector that has been modified to contain the primary gene for the human survival motor neuron (SMN) protein, which is lacking or mutated in people with SMA. When injected, the vector is expected to carry the gene into the nerve cells, enabling production of sufficient amounts of SMN. It is administered intravenously.

Onasemnogene abeparvovec intrathecal (OAV101 IT) is a one-time gene therapy for patients with SMA, proposed to treat people with SMA aged 2 years and over. This intrathecal injection will be used to treat a distinct population from the indication for Zolgensma®.

Following market engagement and review of capable providers, the Commissioner will consider the most appropriate PSR process(es) to formally commission each service.

Interested parties may respond to this Market Engagement Exercise in partnership with other organisations as part of a consortium, subject to them appointing a consortium lead to act on their behalf as the lead contracting party would take overall responsibility for delivery of the service(s) in accordance with the requirements of any future contract(s) if successful.

To express interest and participate in the Market Engagement Exercise, please register and apply via Atamis esourcing portal <https://health-family.force.com/s/Welcome>
Should Tenderers have any queries, or problems using the portal, they should contact the Helpdesk at:

Phone: 08000988201

E-mail: support-health@atamis.co.uk

The closing date for completed Market Engagement responses is 12:00pm (noon), on Monday 2nd February 2026.

Atamis Project reference C410884.

II.2.5) Award criteria

Price

II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Duration in months

108

II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

II.3) Estimated date of publication of contract notice

12 March 2026

Section IV. Procedure

IV.1) Description

IV.1.8) Information about the Government Procurement Agreement (GPA)

The procurement is covered by the Government Procurement Agreement: Yes

Section VI. Complementary information

VI.4) Procedures for review

VI.4.1) Review body

NHS Arden and Greater East Midlands Commissioning Support Unit

Cardinal Square, 10 Nottingham Road

Derby

DE1 3QT

Country

United Kingdom

Internet address

<https://www.ardengemcsu.nhs.uk/>